

Table: Epoxidation of Vinylsulphones 4-8

Vinylsulphone	R	R'	Oxirane	Time, h	Temp, °C	Syn/Anti ratio	Yield, %
4a	Me	H	9a	4	-20	3:1	56
5a	Me	Ph ₃ Si	10a	16	-20	3:1	77
6a	Me	^t BuPh ₂ Si	11a	1	-20 to r.t.	4:1	64
7a	Me	ⁱ Pr ₃ Si	12a	2	-20 to 0	10:1	94
8a	Me	MEM	13a	2	-20 to 0	1:1.5	63
4b	ⁿ Pr	H	9b	3	-20	3:1	80
5b	ⁿ Pr	Ph ₃ Si	10b	1	-20 to 0	2:1	71
6b	ⁿ Pr	^t BuPh ₂ Si	11b	4	-20 to r.t.	1.5:1	66
7b	ⁿ Pr	ⁱ Pr ₃ Si	12b	1	-20 to r.t.	4:1	92
8b	ⁿ Pr	MEM	13b	2	-20 to 0	1:5	65
4c	ⁱ Pr	H	9c	3	-20	25:1	46
5c	¹ Pr	Ph ₃ Si	10c	1	-20 to r.t.	1:25	79
6c	¹ Pr	^t BuPh ₂ Si	11c	4	-20 to r.t.	1:4	89
7c	¹ Pr	¹ Pr ₃ Si	12c	16	-20 to r.t.	1:40	96
8c	ⁱ Pr	MEM	13c	6	-20 to r.t.	1:30	55

The stereochemistry of the major isomer 10a, *syn* derived from epoxidation of 6a, with R = methyl, was established by X-ray crystallography (Figure 1).¹⁰ Chemical correlation of all the other compounds 9a, 11a, 12a and 13a with this material allowed the unambiguous assignment of stereochemistry for these examples. The stereochemistry of the oxiranes 9b-13b, with R = ⁿPr was established by correlation, and by comparison of ¹H and ¹³C nmr spectra with the methyl series. The stereochemistry of the major isomer 12c, *anti* derived from epoxidation of 7c, with R = ¹Pr, was also established by X-ray crystallography (Figure 2).¹¹ This allowed the unambiguous assignment of stereochemistry for 9c, 10c, 11c and 13c, again by correlation.




Figure 1




Figure 2

The stereochemical outcome of the nucleophilic epoxidation reaction is clearly dependent on the nature of the alkyl substituent. The results from the epoxidation of the methyl series **4a–7a** and propyl series **4b–7b** can be accounted for using the extended Felkin–Ahn^{1,2} model in which the γ -alkoxy substituent is orthogonal to the π -system and *anti* to the direction of nucleophilic attack by lithium *t*-butyl hydroperoxide, and the alkyl substituent occupies the less hindered inside position (Figure 3). This arrangement leads to the *syn* product. If a similar conformation represents the reactive arrangement in epoxidation of **8a** and **8b**, then chelation control by the MEM group could account for the reversal of diastereofacial selectivity to give the *anti* product.




Figure 3

The stereochemical results obtained from epoxidation of the isopropyl series **4c–8c** are more difficult to rationalise. In the case of the free hydroxyl compound **4c**, the same model used for the epoxidation of the methyl series appears to provide a satisfactory rationalisation, with the *syn* product being favoured. Presumably the requirement for the allylic C–O bond to be *anti* to the direction of nucleophilic attack is particularly marked for the alkoxide anion, which is likely to be formed under the basic conditions of the reaction. However for the remaining examples (**5c–8c**), the presence of two bulky substituents makes the application of simple models rather difficult. If, as seems reasonable, the ¹Pr group is now the largest group, a different reactive conformation in which the ¹Pr group is *anti* and the oxygen–substituent is inside could now be important (Figure 4). Yamamoto has suggested a similar arrangement for the Lewis acid promoted addition of organocopper reagents to γ -alkoxy- α,β -unsaturated esters.^{3a} Nucleophilic attack would occur from below with both non-chelating (**5c–7c**) and chelating substituents **8c**, leading to the *anti* products in all cases. It should be noted that nucleophilic epoxidation of the closely related enone **14** also gave an *anti* product **15** with high diastereoselectivity.^a




Figure 4

Whatever the rationalisation of the stereochemical outcome of these nucleophilic epoxidation reactions, both *syn* (by silylation of **9c**) and *anti* diastereoisomers of the oxirane **12c** are readily available, and the *syn* diastereoisomer of the oxirane **12a** is also available with reasonable selectivity.

Acknowledgements: We thank the SERC for a postgraduate studentship (S.P.S.) and for a research grant (W.C.), and Dr. M. Ashwell for some preliminary experiments.

References

1. Ashwell, M.; Clegg, W.; Jackson, R.F.W. *J. Chem. Soc., Perkin Trans. 1* **1991**, 897–908.
2. Alcaraz, C.; Carretero, J.C.; Dominguez, E. *Tetrahedron Lett.* **1991**, *32*, 1385–1388.
3. For some representative recent experimental work, see: (a) Yamamoto, Y.; Nishii, S.; Ibuka, T. *J. Chem. Soc., Chem. Commun.* **1987**, 464–466. (b) Larcheveque, M.; Tamagnan, G.; Petit, Y. *J. Chem. Soc., Chem. Commun.* **1989**, 31–33. (c) Reetz, M.T.; Röhrig, D. *Angew. Chem. Int. Ed. Engl.* **1989**, *28*, 1706–1709. (d) Bernardi, A.; Cardani, S.; Scolastico, C.; Villa, R. *Tetrahedron* **1990**, *46*, 1987–1998. (e) Leonard, J.; Ryan, G.; Swain, P.A. *Synlett* **1990**, 613–614. (f) Barrett, A.G.M.; Lebold, S.A. *J. Org. Chem.* **1990**, *55*, 3853–3857. For earlier references, see those cited in 4a and 4b below.
4. For theoretical discussions, see: (a) Dorigo, A.E.; Morokuma, K. *J. Am. Chem. Soc.* **1989**, *111*, 6524–6536; (b) Bernardi, A.; Capelli, A.M.; Gennari, C.; Scolastico, C. *Tetrahedron: Asymmetry* **1990**, *1*, 21–32.
5. Fuchs, P.L.; Braish, T.F.; *Chem. Rev.* **1986**, *86*, 903–917.
6. (a) Kitamura, M.; Isobe, M.; Ichikawa, Y.; Goto, T. *J. Org. Chem.* **1984**, *49*, 3517–3527; (b) Isobe, M.; Ichikawa, Y.; Funabashi, Y.; Mio, S.; Goto, T. *Tetrahedron* **1986**, *42*, 2863–2872; (c) Ichikawa, Y.; Isobe, M.; Bai, D.; Goto, T. *Tetrahedron* **1987**, *43*, 4737–4748.
7. Cardani, S.; Bernardi, A.; Colombo, L.; Gennari, C.; Scolastico, C.; Venturini, I. *Tetrahedron* **1988**, *44*, 5563–5572.
8. Yamamoto, K.; Yamamoto, N. *Chemistry Lett.* **1989**, 1149–1152.
9. (a) Dominguez, E.; Carretero, J.C. *Tetrahedron* **1990**, *46*, 7197–7206. (b) Trost, B.M.; Grese, T.A. *J. Org. Chem.* **1991**, *56*, 3189–3192. We had independently discovered this reaction in 1988: Ashwell, M.; Hindley, N.G.; Jackson, R.F.W. presented at the symposium in honour of Prof. R.A. Raphael, Cambridge, 22nd July, 1988.
10. Compound **10a** forms monoclinic crystals, $a = 11.642(1)$, $b = 7.852(1)$, $c = 28.092(3)$ Å, $\beta = 91.37(1)^\circ$, $Z = 4$, space group $P2_1/c$. The structure was solved from 2699 diffractometer reflections with $F > 4\sigma(F)$ and $2\theta < 50^\circ$ (MoK α radiation) and refined to $R = 0.0564$ and $R_w = 0.0565$.
11. Compound **12c** forms triclinic crystals, $a = 8.192(2)$, $b = 11.734(3)$, $c = 13.236(3)$ Å, $\alpha = 109.15(2)$, $\beta = 100.83(1)^\circ$, $\gamma = 95.65(1)^\circ$, $Z = 2$, space group $P\bar{1}$. The structure was solved from 2976 diffractometer reflections with $F > 4\sigma(F)$ and $2\theta < 50^\circ$ (MoK α radiation) and refined to $R = 0.0386$ and $R_w = 0.0470$.
12. Chérest, M.; Felkin, H.; Prudent, N. *Tetrahedron Lett.* **1968**, 2199–2204. Chérest, M.; Felkin, H. *Tetrahedron Lett.* **1968**, 2205–2208. Anh, N.T.; Eisenstein, O. *Nouv. J. Chem.* **1977**, *1*, 61–70.

(Received in UK 26 June 1991)